We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.
- Authors
Creutzig, U; Dworzak, M N; Zimmermann, M; Bourquin, J-P; Gruhn, B; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Stackelberg, A v; Starý, J; Reinhardt, D
- Abstract
The article discusses a study which aimed to improve outcome of high-risk (HR) patients by adding moderately dosed 2-chloro-2-deoxyadenosine (2-CDA) to the respective consolidation treatment backbone without increasing the toxicity. The treatment plan included randomization during induction with either liposomal daunorubicin or idarubicin. It suggests that moderate dose 2-CDA does not improve prognosis in HR patients when given during consolidation treatment.
- Subjects
ACUTE myeloid leukemia in children; MYELOID leukemia; DEOXYADENOSINE; DAUNOMYCIN; HEALTH outcome assessment; DRUG dosage; PROGNOSIS; LEUKEMIA treatment; THERAPEUTICS; ANTINEOPLASTIC agents; ADENOSINES; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; RESEARCH; EVALUATION research; RANDOMIZED controlled trials; ACUTE myeloid leukemia
- Publication
Leukemia (08876924), 2015, Vol 29, Issue 11, p2260
- ISSN
0887-6924
- Publication type
letter
- DOI
10.1038/leu.2015.94